3rd Quarter - Amendment

FRESENIUS KABI USA LLC for FRESENIUS KABI USA LLC

Firm
Client
Income
—
Expenses
$340,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report Oct 17, 2025 $320,000 Replaced
3rd Quarter - Amendment (this page) Nov 25, 2025 $340,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Drug Shortages Domestic Manufacturing Tariffs

LobbyistCovered position, as disclosed
CRAIG BURTON —

Contacted: White House Office; SENATE; Office of Management & Budget (OMB); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC)

Medicare/Medicaid MMM

Drug Shortages and Medicaid ERISA Fiduciary Duty IRA Reform

LobbyistCovered position, as disclosed
CRAIG BURTON —
SARAH CHRISTINE D'ORSIE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act S. 1414/H.R._: Expedited Access to Biosimilars Act S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 1041: Affordable Prescriptions for Patients Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 43: Skinny Labels, Big Savings Act S. 1097/H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 HR 4317: PBM Reform Act of 2025 HR 2214: DRUG Act S. 1553/H.R. 3160: PREVAIL Act S. 2305: Biosimilar Red Tape Elimination Act S. 2658: Medication Affordability and Patient Integrity Act ERISA Fiduciary Duty PTAB Discretionary Denials IRA Reform Human Factor Studies Interchangeability Biosimilar User Fee Act (BsUFA) Drug Shortages Domestic Manufacturing

LobbyistCovered position, as disclosed
CRAIG BURTON —
SARAH CHRISTINE D'ORSIE —
STEVEN CHASE WALKER —

Contacted: White House Office; SENATE; Office of Management & Budget (OMB); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: S. 1553 (119th), S. 1414 (119th), H.R. 5526 (119th), S. 1096 (119th), S. 1097 (119th), S. 43 (119th), S. 2658 (119th), H.R. 4570 (119th), S. 1041 (119th), H.R. 3269 (119th), H.R. 4317 (119th), S. 2305 (119th), H.R. 2214 (119th), H.R. 3160 (119th), S. 2276 (119th), S. 1954 (119th)

Manufacturing MAN

Domestic Manufacturing

LobbyistCovered position, as disclosed
CRAIG BURTON —

Contacted: Office of Management & Budget (OMB); White House Office; Food & Drug Administration (FDA)

Budget/Appropriations BUD

Domestic Manufacturing Tariffs

LobbyistCovered position, as disclosed
CRAIG BURTON —

Contacted: Office of Management & Budget (OMB); White House Office

Copyright/Patent/Trademark CPT

PTAB Discretionary Denials

LobbyistCovered position, as disclosed
SARAH CHRISTINE D'ORSIE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.